UnknownPhase 1

A Study of Anginera In Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery

United States12 participantsStarted 2006-04

Plain-language summary

This is a first in man, Phase I safety study of Anginera in adults with Left Ventricular Dysfunction (LVD) and Reversible Myocardial Ischemia undergoing a CABG procedure.

Who can participate

Age range35 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Patient undergoing valve replacement or valve modification
✕. Patient with significant or malignant ventricular arrhythmias, defined as a patient being treated for ventricular tachycardia and/or ventricular fibrillation with an implantable cardioverter/defibrillator (ICD) or a patient being treated with Amiodarone for these same tachyarrhythmias. (Note: having an implantable cardioverter/defibrillator (ICD) per se, in a patient who does not have significant or malignant ventricular arrhythmias, does not exclude the patient from this study.)
✕. Patient requires urgent coronary artery bypass surgery

What they're measuring

Physical exam and interval medical history

CBC and differential

Serum cardiac markers-Troponin I

Serum chemistries and urinalysis

Resting electrocardiogram (ECG)

24 hour Holter monitor

Adverse Events reporting

Trial details

NCT IDNCT00364390

SponsorTheregen, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2008-11

View on ClinicalTrials.gov More Coronary Artery Disease trials